证券代码：301166 证券简称：优宁维 公告编号：2025-057 一、回购公司股份的进展情况 截至 2025 年 6 月 30 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 0 股，占公司总股本的 0%，公司暂未实施本次股份回购。 本次回购股份符合相关法律、行政法规、规范性文件及公司回购股份方案等 有关规定。 二、其他说明 公司回购股份符合《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》及公司回购股份方案的相关规定，具体如下： 1、公司未在下列期间回购公司股份： 上海优宁维生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 10 日召 开第四届董事会第四次会议、第四届监事会第四次会议，于 2025 年 5 月 13 日召 开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公 司使用不低于人民币 1,500 万元（含本数），不高于人民币 3,000 万元（含本数） 的自有资金以 ...

Core Viewpoint - On June 30, a total of 31 listed companies had their restricted shares unlocked, with a total market value of approximately 31.50 billion yuan [1]. Group 1: Unlocking Details - The specific details of the restricted share unlocks include: - Meili Ecology (000010): 239 million shares from A-share issuance to original shareholders - Xingrong Environment (000598): 4.926 million shares from equity incentive lock-up - Yueyang Xinchang (000819): 526,800 shares from equity incentive lock-up - Gaohong Co., Ltd. (000851): 4.944 million shares from equity incentive lock-up - Zhongyan Chemical (600328): 470,460 shares from equity incentive lock-up - Yangnong Chemical (600486): 115,480 shares from equity incentive lock-up - Kangyuan Pharmaceutical (600557): 2.6093 million shares from equity incentive lock-up - Keda Technology (002518): 1.3953 million shares from equity incentive lock-up - Longci Technology (300835): 562,700 shares from equity incentive lock-up - Weiming Environmental Protection (603568): 3.129 million shares from equity incentive lock-up - Dongrui Co., Ltd. (001201): 486,400 shares from A-share issuance to original shareholders - Sanwei Co., Ltd. (603033): 1.183 million shares from equity incentive lock-up - Naer Co., Ltd. (002825): 140,000 shares from equity incentive lock-up - Jinyinhe (300619): 1.6248 million shares from A-share issuance to legal persons - Tianyuan Environmental Protection (301127): 14.6 million shares with extended lock-up period - Youningwei (301166): 40.6188 million shares with extended lock-up period - Xutian Salt Industry (600929): 3.033 million shares from equity incentive lock-up - Keli Sensor (603662): 722,800 shares from equity incentive lock-up - Gongniu Group (603195): 641,200 shares from equity incentive lock-up - Fuyuan Pharmaceutical (601089): 27.5 million shares from pre-issue lock-up - Xinbang Intelligent (301112): 7.4097 million shares from pre-issue lock-up - Shanghai Port Bay (605598): 29,400 shares from equity incentive lock-up - Dingjide (603255): 507,500 shares from equity incentive lock-up - United Precision (001268): 6.154 million shares from pre-issue lock-up - Pinggao Co., Ltd. (688227): 48.9585 million shares - Chunli Medical (688236): 20.9 million shares - Zhongwulian (688297): 40.3 million shares - Lais Information (688631): 163,480 shares - Shichuang Energy (688429): 200,000 shares - Xindong Link (688582): 220,840 shares - Aike Saibo (688719): 100,000 shares [2].

Group 1 - Shanghai Youning Biological Technology Co., Ltd. won a bid for reagent procurement from Shandong First Medical University, with a total transaction amount of 7403.70 RMB [1] - The procurement includes multiple items, all supplied by CST, a manufacturer based in the United States [2] - Each item has a unit price of 2467.90 RMB, with a delivery requirement of within 7 days after contract signing [1][2] Group 2 - The items procured include K63-linkage Specific Polyubiquitin, Phospho-NF-κB p65, and NLRP3 Rabbit mAbs, each with a specification of 100ul [2] - The procurement emphasizes standard service for warranty and after-sales support [1][2] - Payment is contingent upon successful delivery and acceptance of the goods [1]

证券代码：301166 证券简称：优宁维 公告编号：2025-056 上海优宁维生物科技股份有限公司 关于首次公开发行前部分已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 3、本次拟解除限售的股份原定上市流通日为 2025 年 6 月 28 日，因 2025 年 6 月 28 日为非交易日，故上市流通日期顺延至下一交易日 2025 年 6 月 30 日（星 期一）。 一、首次公开发行股份概况 经中国证券监督管理委员会《关于同意上海优宁维生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册，并经深圳 证券交易所《关于上海优宁维生物科技股份有限公司人民币普通股股票在创业板 上市的通知》（深证上〔2021〕1336 号）同意，公司首次向社会公众公开发行人 民币普通股（A 股）股票 21,666,668 股，于 2021 年 12 月 28 日在深圳证券交易 所上市交易。首次公开发行前总股本 65,000,000 股，首次公开发行股票完成后公 司总股本为 86,666,668 股，其 ...

民生证券股份有限公司 性公告》（公告编号：2022-090）。 截至本核查意见出具日，公司总股本为 86,666,668 股，其中尚未解除限售的 股份数量为 45,397,800 股。 关于上海优宁维生物科技股份有限公司 首次公开发行前部分已发行股份上市流通的核查意见 民生证券股份有限公司（以下简称"保荐机构"）作为上海优宁维生物科技 股份有限公司（以下简称"优宁维"或"公司"）首次公开发行股票并在创业板 上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证 券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关法律法规和规范性文件的规定，对优宁维 首次公开发行前部分已发行股份上市流通的事项进行了核查，具体核查情况如下： 一、首次公开发行股份情况 经中国证券监督管理委员会《关于同意上海优宁维生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册，并经深圳 证券交易所《关于上海优宁维生物科技股份有限公司人民币普通股股票在创业板 上市的通知》（深证上〔2021〕1336 号）同意，公司首次向社会公 ...

Core Points - The stock price of You Ning Wei (301166) closed at 29.86 yuan on June 13, 2025, with no change from the previous week, and reached a high of 30.65 yuan on June 10, 2025 [1] - The total market capitalization of You Ning Wei is 2.588 billion yuan, ranking 48th out of 50 in the biopharmaceutical sector and 4527th out of 5150 in the A-share market [1] - A block trade occurred on June 9, 2025, with a transaction amount of 6.576 million yuan [1] - Shareholders Shanghai Chuangye Jieli Tai Li Venture Capital Center and Shanghai Tai Li Venture Capital Management reduced their holdings by 462,400 shares, representing 0.5336% of the total share capital, during a period when the stock price increased by 1.14% [1] Company Announcements - You Ning Wei announced the cancellation of a special account for raised funds, with a total of 21,666,668 shares issued at a price of 8,606 yuan per share, raising a total of 18.646 billion yuan [2] - After deducting issuance costs of 269.1162 million yuan, the net amount raised was 15.955173 billion yuan, with all funds received and verified by Tianzhi International Accounting Firm [2] - The company has closed some special accounts for raised funds, including the cancellation of an account at Bank of China, with surplus funds of 396,227 yuan transferred to the general account for daily operational liquidity [2]

Group 1 - The company has announced the cancellation of a special account for raised funds, transferring the remaining balance of RMB 3,962.27 to its general account for daily operational liquidity [4][6] - The total amount raised from the initial public offering (IPO) was RMB 186,463.34 million, with a net amount of RMB 159,551.73 million after deducting issuance costs [2][3] - The company had established a special account for the management and storage of raised funds, in compliance with regulatory requirements and signed a tripartite supervision agreement with the sponsor and the bank [3][4] Group 2 - The cancellation of the special account was conducted to streamline bank account management and reduce administrative costs [4] - The company has completed the necessary procedures for the cancellation of the special account, which also terminates the related supervision agreement [4][6] - The raised funds were subject to specific management protocols to protect investor interests, as outlined in various regulatory documents [3]

Fundraising Overview - The company successfully raised a net amount of RMB 26,911.62 million after deducting issuance costs from the initial public offering of 21,666,668 shares [1] - The funds have been fully received and verified by Tianzhi International Accounting Firm [1] Fund Management and Usage - The company has established a special account for the management and storage of the raised funds, in compliance with relevant regulations and internal management policies [1] - A tripartite supervision agreement has been signed with the sponsoring institution and the bank to ensure proper management of the funds [1] Fund Account Status - The company has detailed the status of its fundraising special accounts, including various projects such as online marketing network construction, offline service network upgrades, and research center construction [1] - Specific accounts have been opened at banks like Ping An Bank and Industrial and Commercial Bank of China for different projects [1] Account Cancellation - The company has canceled a fundraising special account with a balance of RMB 3,962.27, transferring the remaining funds to its general account for daily operational liquidity [2] - The cancellation of the account has been completed, and the corresponding regulatory agreement has also been terminated [2]

证券代码：301166 证券简称：优宁维 公告编号：2025-055 上海优宁维生物科技股份有限公司 关于注销募集资金专项账户的公告 （一）本次注销的募集资金专户基本情况 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，上海优宁维生物科技股份有限公司（以下简称"公司"） 首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为人民币 1.00 元，发行价格为人民币 86.06 元/股，募集资金总额为人民币 186,463.34 万元， 扣除发行费用人民币 26,911.62 万元（不含税）后，实际募集资金净额为人民币 159,551.73 万元。 上述募集资金已全部到账，天职国际会计师事务所（特殊普通合伙）已对上 述资金到位情况进行了审验，并出具了天职业字[2021]45819 号《验资报告》。 上述募集资金到账后，公司对募集资金的存放和使用进行专户管理，并与专 户银行、保荐机构签订了《募集资金三方监管协议》。 二、募集资金的存放和管理情况 为 ...

权益变动性质：减少 签署日期：2025年6月10日 1 上海优宁维生物科技股份有限公司 简式权益变动报告书 上市公司名称：上海优宁维生物科技股份有限公司 信息披露义务人一：上海创业接力泰礼创业投资中心（有限合伙） 住所及通讯地址：上海市闵行区庙泾路66号G563室 信息披露义务人二：上海泰礼创业投资管理有限公司－上海含泰创业投资合伙企 业（有限合伙） 住所及通讯地址：上海市闵行区园文路28号306-A室 信息披露义务人声明 一、本权益变动报告书依据《公司法》《证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相 关的法律、法规规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《上市公司收购管理办法》的规定，本报告书已全面披 露信息披露义务人在优宁维中拥有权益的股份变动情况。截至本报告书签署日， 除本报告书披露的信息外，上述信息披露义务人没有通过任何其他方式增加或减 少其在优宁维中拥有权益的股份。 四、本次权益变动是根据本报告书所载明的资料进行的。除本信息披露义务 人外，没有委托或者授权其他任何人提供未在本报告书列载的信息 ...